



Eagle Health Holdings Limited

ASX Announcement

9 May 2019

Eagle Health Continues Expansion, Integration and Development

Makes Key Advisory Appointment

Eagle Health Holdings Limited (ASX: EHH) (“Eagle Health” or “Company”) continues its multi-dimensional integration of opportunities in a deliberate strategy matrix of geographic, production and marketing opportunities.

To assist in the facilitation of this plan, the Company has engaged Sydney based corporate advisory firm, Crestbridge Capital Pty Ltd (“**Crestbridge**”) to assist the Company and act as Corporate Advisors and Transaction Facilitators as EHH seeks to aggressively implement the acquisition component of its growth model.

Crestbridge will work with Mr. Zhang, Managing Director of Eagle Health and his corporate team to source, secure and execute value accretive merger and acquisition opportunities for the Company. Crestbridge will also work towards creating greater market awareness of EHH and recommend capital project funding options.

EHH recently announced expansion plan in its Traditional Chinese Medicine (“TCM”) product range and offering. Integral to that announcement is the plan to source natural, reliable, high quality raw materials and establish TCM production, including Hemp, facilities from Australia.

This strategy will be one of the foundations to support the new TCM product that was announced in August 2018.

Mr. Zhang reaffirmed his comments on this appointment: *“we have been working towards an Australian operating presence. With the rollout of this strategy, we continue our development as an international company, initially focusing in South East Asia, with an immediate presence in China and Australia. We will source and manufacture product in the most opportunistic geographic and continue to increase our marketing position.”*

As recently stated, Australian products have always been trusted by Chinese consumers because of their clean green reputation. There will also be a natural attraction towards clean, green, organic Australian grown agricultural produce. This long-standing reputation will be utilized by EHH in the marketing of Australian sourced TCM and Herbal produce such as Hemp.

Once established, these facilities will be continually enhanced and enlarged organically and by acquisition, to produce and meet the growing demand for TCM for the Company’s retail growth strategy of:

- leveraging its existing 276 traditional Chinese distributors; and
- Increasing numbers of Education and Experience stores.

As part of the service mandate with Crestbridge, the Company will issue 200,000 fully paid ordinary shares (**Shares**) subject to 6 months voluntary escrow and 200,000 free attaching options with exercise price of \$0.45 each, expiring 31 January 2020.

-END



Eagle Health Holdings Limited

CONTACT

Steven Shao

Investor Relations

T: +61 3 8593 7378

E: steven@aeuhh.com.au

Kobe Li

Company Secretary

T: +61 3 8593 7378

E: kobeli@aeuhh.com.au

About Eagle Health Holdings Limited

Eagle Health is an ASX listed vertically integrated health and nutritional products business which develops, manufactures and distributes products into 26 provinces in China. Eagle Health produces a range of traditional Chinese Medicine and Western nutritional products including amino acids, protein supplements, lozenges and dendrobium oil. Eagle Health has a GMP certified manufacturing facility and a Head Office in Xiamen, China, acting as a central hub for distribution into Chinese pharmacies, health food stores, trading companies and supermarkets. Eagle Health has a corporate and sales office in Melbourne, Australia. Eagle Health has a stated strategy of acquiring or partnering with quality Australian products for distribution into China and in 2017 a pre-meal shake for Type 2 diabetes, branded Hutang 1, was licensed from Omni Innovation in Australia.

For more information visit: www.aeuhh.com.au or www.eaglehealthltd.com/EN/index.aspx